M&A Deal Summary

Questcor Pharmaceuticals Acquires Rights to Synacthen

On June 11, 2013, Questcor Pharmaceuticals acquired life science company Rights to Synacthen from Novartis for 60M USD

Acquisition Highlights
  • This is Questcor Pharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is Questcor Pharmaceuticals’ largest (disclosed) transaction.
  • This is Questcor Pharmaceuticals’ 2nd transaction in the United States.

M&A Deal Summary
Date 2013-06-11
Target Rights to Synacthen
Sector Life Science
Buyer(s) Questcor Pharmaceuticals
Sellers(s) Novartis
Deal Type Divestiture
Deal Value 60M USD

Target

Rights to Synacthen

United States
Synacthen® and Synacthen Depot® in certain countries outside the U.S. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is a depot formulation of Synacthen. The products are approved outside the U.S. for certain autoimmune and inflammatory conditions, but have never been developed or approved for patients in the U.S.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Questcor Pharmaceuticals

Anaheim, California, United States
Category Company
Founded 1990
Sector Life Science
DESCRIPTION

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company that provides drugs for the treatment of autoimmune and inflammatory disorders.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 2 of 2
Type (Divestiture) 2 of 2
Country (United States) 2 of 2
Year (2013) 2 of 2
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-01-02 BioVectra

Charlottetown, Prince Edward Island, Canada

BioVectra is a provider of contract manufacturing services to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients (API's), chemical intermediates, and bioprocessing reagents. BioVectra was founded in 1970 and is based in Charlottetown, Prince Edward Island.

Buy CA$50M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-09-10 BioVectra

Charlottetown, Prince Edward Island, Canada

BioVectra is a provider of contract manufacturing services to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients (API's), chemical intermediates, and bioprocessing reagents. BioVectra was founded in 1970 and is based in Charlottetown, Prince Edward Island.

Sell $250M

Seller(S) 1

SELLER

Novartis

Basel, Switzerland
Category Company
Founded 1996
Sector Life Science
Employees104,323
Revenue 46.7B USD (2023)
DESCRIPTION
Novartis' corporate campus in Basel, Switzerland.
Novartis' corporate campus in Basel, Switzerland.

Novartis is a global healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.

DEAL STATS #
Overall 2 of 7
Sector (Life Science) 2 of 4
Type (Divestiture) 1 of 6
Country (United States) 1 of 2
Year (2013) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-12-17 Vivacta

Sittingbourne, United Kingdom

Vivacta Limited is a medical diagnostic company developing proprietary sensors and readers for rapid, point-of-care (PoC) testing. The company is applying piezofilm technology to achieve extremely high sensitivity and wide dynamic range for a new generation of diagnostic products adapted to near-patient testing and has generated an independent intellectual property position comprising over 15 patent families.

Buy $90M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-02-17 CoStim Pharmaceuticals

Boston, California, United States

CoStim is is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

Buy -
Mergr

Product

Company

Legal